This educational series is supported by independent educational grants from AstraZeneca and Merck.

CME Available: https://auau.auanet.org/node/31198

Based on the documented need from the 2019 AUA global needs assessment in advanced prostate cancer, the AUA has produced a new series of educational offerings for the urologic care team focused on PARP inhibitors (PARPi). The first of three in the series PARP Inhibitors: Assessing the Rapidly Evolving Treatment Landscape will address the latest developments in PARPi treatments and advanced prostate cancer care.

Upon completion of this activity, participants will be able to:

1. Review recommended criteria for genetic testing of prostate cancer patients and the options for testing these men.

2. Explain importance of testing for germline pathogenic variants and their implication for utilizing novel targeted therapies such as PARP inhibitors and for cascade testing among patient family members.

3. Identify men with BRCA1/2 pathogenic variants and variants in other key inherited syndromes, regarding their prostate cancer and other cancer risk, and implement strategies for cancer screening and management.